Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis-Reference-Cited by-同舟云学术

Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

Published:2010-07 Issue:1 Volume:177 Page:415-423
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Benedettini Elisa,Sholl Lynette M.,Peyton Michael,Reilly John,Ware Christopher,Davis Lenora,Vena Natalie,Bailey Dyane,Yeap Beow Y.,Fiorentino Michelangelo,Ligon Azra H.,Pan Bo-Sheng,Richon Victoria,Minna John D.,Gazdar Adi F.,Draetta Giulio,Bosari Silvano,Chirieac Lucian R.,Lutterbach Bart,Loda Massimo

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference34 articles.

1. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations;Asahina;Br J Cancer,2006

2. The role of gefitinib in the management of Asian patients with non-small cell lung cancer;Chang;Expert Opin Investig Drugs,2008

3. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations;Inoue;J Clin Oncol,2006

4. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer;Jackman;J Clin Oncol,2007

5. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy;Sunaga;Lung Cancer,2007

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment;International Journal of Molecular Sciences;2024-08-22

2. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation;Cancers;2024-03-31

3. Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC;European Journal of Medicinal Chemistry;2024-01

4. A review of recent advances in the molecular mechanisms underlying brain metastasis in lung cancer;Molecular Cancer Therapeutics;2023-12-20

5. NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study;Molecular Oncology;2023-10-28